Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -74.75% is 84% above its 5-year average of -457.23%, near the high end of its 5-year range (-1861.60%–57.37%).
89.26% above its 12-month average of -696.01%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1269.64%.
NET PROFIT MARGIN
-74.75%
NET PROFIT MARGIN AVG TTM
-696.01%
NET PROFIT MARGIN AVG 3Y
-564.35%
NET PROFIT MARGIN AVG 5Y
-457.23%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+89.26%
CURRENT VS 3Y AVG
+86.75%
CURRENT VS 5Y AVG
+83.65%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-28650.00%
vs the sector median at left
IDEAYA Biosciences, Inc.
Market Cap
$3.49B
Net Profit Margin
-74.75%
TTM Avg
-696.01%
3Y Avg
-564.35%
5Y Avg
-457.23%
Market Cap
$3.51B
Net Profit Margin
-4612.13%
TTM Avg
-2306.07%
3Y Avg
-1485.27%
5Y Avg
-1076.43%
Market Cap
$3.53B
Net Profit Margin
-229.92%
TTM Avg
-236.29%
3Y Avg
-296.56%
5Y Avg
-337.05%
Market Cap
$3.44B
Net Profit Margin
-6755.78%
TTM Avg
-10397.28%
3Y Avg
-7288.11%
5Y Avg
-5606.97%
Market Cap
$3.56B
Net Profit Margin
20.37%
TTM Avg
9.12%
3Y Avg
-3.67%
5Y Avg
-13.14%
Market Cap
$3.55B
Net Profit Margin
-1.69%
TTM Avg
-12.55%
3Y Avg
-19.61%
5Y Avg
-21.06%
Market Cap
$3.38B
Net Profit Margin
33.42%
TTM Avg
30.07%
3Y Avg
2.48%
5Y Avg
-14.75%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | $3.49B | -74.75% | -696.01% | -564.35% | -457.23% |
| Celcuity Inc. (CELC)vs › | $3.49B | 0.00% | 0.00% | 0.00% | 0.00% |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.51B | -4612.13% | -2306.07% | -1485.27% | -1076.43% |
| Tango Therapeutics, Inc. (TNGX)vs › | $3.53B | -229.92% | -236.29% | -296.56% | -337.05% |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.44B | -6755.78% | -10397.28% | -7288.11% | -5606.97% |
| Veracyte, Inc. (VCYT)vs › | $3.56B | 20.37% | 9.12% | -3.67% | -13.14% |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.55B | -1.69% | -12.55% | -19.61% | -21.06% |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 33.42% | 30.07% | 2.48% | -14.75% |
| CareDx, Inc (CDNA)vs › | $3.38B | 24.23% | 5.06% | -20.39% | -16.94% |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.33B | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Margin
-72.8%
Net Profit Margin
-74.8%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -1269.64% |
| 2026-03-31 | -1502.12% |
| 2025-12-31 | -765.66% |
| 2025-09-30 | 57.37% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | -1861.60% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | -865.54% |
| 2023-09-30 | -341.38% |
| 2023-06-30 | -787.98% |
| 2023-03-31 | -300.00% |
| 2022-12-31 | -601.72% |
| 2022-09-30 | 5.44% |
| 2022-06-30 | -376.96% |
| 2022-03-31 | -123.36% |
| 2021-12-31 | -614.65% |
| 2021-09-30 | -129.03% |
| 2021-06-30 | -125.02% |
| 2021-03-31 | -124.48% |
| 2020-12-31 | -48.58% |
| 2020-09-30 | -54.93% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
